Used in research for treating hormone-resistant prostate cancer by targeting heat shock protein 90 (HSP90), which helps stabilize proteins involved in cancer cell growth and survival. Inhibiting HSP90 leads to degradation of these proteins, potentially stopping tumor progression. Also studied in other cancers like breast and lung due to its ability to disrupt multiple signaling pathways linked to tumor development. Shows activity against cancer cells resistant to conventional therapies, making it a candidate for overcoming drug resistance. Currently in preclinical and early clinical evaluation, not approved for routine clinical use.